Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic castration-resistant prostate cancer Age: Adult Condition: Previously treated with a docetaxel-containing treatment regimen |
Dose: Injection – 20 mg/m2 Frequency: every three weeks Note: Administered as a one-hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel Injection treatment. |
|
Indication: Metastatic castration-resistant prostate cancer Age: Adult Condition: Select patients at the discretion of the treating healthcare provider |
Dose: Injection – 25 mg/m2 Frequency: every three weeks Note: Administered as a one-hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel Injection treatment. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Safety and efficacy not established Note: Not recommended |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment All severities (not requiring hemodialysis) |
Dose: No dosage adjustment necessary Note: No dosage adjustment necessary |
|
Condition: End-stage renal disease (Creatinine Clearance less than 15 mL/min) |
Dose: Carefully monitor Note: Carefully monitor |
Administration
- For hospital use only
- Must be diluted before use
Side Effect
- Anemia (11-98%)
- Leukopenia (69-96%)
- Neutropenia (82-94%)
- Thrombocytopenia (4-48%)
- Diarrhea (6-47%)
- Fatigue (5-37%)
- Nausea (2-34%)
- Vomiting (2-22%)
- Asthenia (5-20%)
- Constipation (1-20%)
- Abdominal pain (2-17%)
- Hematuria (2-17%)
- Anorexia (1-16%)
- Back pain/arthralgia (11-16%)
- Peripheral neuropathy (1-13%)
- Pyrexia (1-12%)
- Dyspnea (1-12%)
- Cough (11%)
- Dysgeusia (11%)
- Dyspepsia (10%)
- Alopecia (10%)
- Peripheral edema (1-9%)
- Weight loss (9%)
- Dizziness (8%)
- Headache (8%)
- UTI (2-8%)
- Dysuria (7%)
- Febrile neutropenia (1-7%)
- Mucosal inflammation (1-6%)
- Hypotension (5%)
- Arrhythmia (1-5%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole)
|
Increased concentration
|
|
CYP3A inducers (e.g. phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital)
|
Decreased concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Neutrophil Counts > 1,500/mm3
|
Risk of infection complications
|
|
History of Severe Hypersensitivity to Polysorbate 80
|
Risk of severe allergic reaction
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store between 15-30° C. Do not refrigerate.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.